

The challenge of value-based pricing in combination therapies containing trastuzumab and pertuzumab in HER2+ metastatic breast cancer

Expert Review of Pharmacoeconomics and Outcomes Research
21, 497-504

DOI: 10.1080/14737167.2021.1896968

Citation Report

#	ARTICLE	IF	CITATIONS
1	Cost-effectiveness Analysis of Pertuzumab With Trastuzumab in Patients With Metastatic Breast Cancer. JAMA Oncology, 2022, 8, 597.	7.1	15
2	Value elements and methods of value-based pricing for drugs in Japan: a systematic review. Expert Review of Pharmacoeconomics and Outcomes Research, 2023, 23, 749-759.	1.4	4